GI
FOLD

GAMMA Investing’s Amicus Therapeutics FOLD Stock Holding History

GAMMA Investing’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,432
Closed -$35.2K – 4178
2026
Q1 		$35.2K Buy
2,432
+445
+22% +$6.38K ﹤0.01% 2417
2025
Q4 		$28.3K Buy
1,987
+1,243
+167% +$12.2K ﹤0.01% 2421
2025
Q3 		$5.86K Buy
744
+724
+3,620% +$5.15K ﹤0.01% 3108
2025
Q2 		$115 Sell
20
-892
-98% -$5.76K ﹤0.01% 3746
2025
Q1 		$7.44K Buy
912
+477
+110% +$4.41K ﹤0.01% 2887
2024
Q4 		$4.1K Sell
435
-503
-54% -$5.23K ﹤0.01% 2995
2024
Q3 		$10K Buy
938
+326
+53% +$3.55K ﹤0.01% 2462
2024
Q2 		$6.07K Buy
612
+363
+146% +$3.73K ﹤0.01% 2490
2024
Q1 		$2.93K Sell
249
-33
-12% -$422 ﹤0.01% 2613
2023
Q4 		$3.5K Buy
+282
New +$3.2K ﹤0.01% 2381

Other funds holding FOLD

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

GAMMA Investing's FOLD Position: Q2 2026 in Review

GAMMA Investing sold out of Amicus Therapeutics (FOLD) in Q2 2026, closing a stake of 2,432 shares — an estimated $35.2K sold.

GAMMA Investing first reported a position in FOLD in Q4 2023 and held it in 10 quarters. The position peaked at $35.2K in Q1 2026. 1 fund tracked by Wall St. Rank holds FOLD as of Q2 2026.

  • GAMMA Investing reported no remaining Amicus Therapeutics position as of Q2 2026 after selling out during the quarter.
  • GAMMA Investing sold 2,432 Amicus Therapeutics shares in Q2 2026, an estimated $35.2K.
  • GAMMA Investing first reported a position in Amicus Therapeutics in Q4 2023 and held it in 10 quarters.
  • GAMMA Investing's Amicus Therapeutics position peaked at $35.2K in Q1 2026.
  • 1 fund tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.